Days after controversy greeted Biogen's blockbuster Alzheimer's OK, the big biotech concedes a setback on the tau front

John Carroll

Editor & Founder

Just days after triggering a maelstrom of controversy with their decision to launch an unproven Alzheimer’s drug with a $56,000 price, Biogen $BIIB is back …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Days after controversy greeted Biogen's blockbuster Alzheimer's OK, the big biotech concedes a setback on the tau front

John Carroll

Editor & Founder

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

FDA meeting to pick next winter's flu shot is canceled, in ominous sign for US vaccine policy

Updated: Lilly joins Trump administration to announce $27B manufacturing commitment

After rejection, Regeneron seeks accelerated approval of bispecific for only one of two types of lymphoma

AstraZeneca’s SERD hits primary endpoint in late-stage trial, but first-line potential remains uncertain

Where the money is: The top 100 venture investors in biotech

How AI can address ongoing challenges in the life sciences industry

Days af­ter con­tro­ver­sy greet­ed Bio­gen's block­buster Alzheimer's OK, the big biotech con­cedes a set­back on the tau front

Editor & Founder

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Days after controversy greeted Biogen's blockbuster Alzheimer's OK, the big biotech concedes a setback on the tau front